Find disease awareness content and relevant supporting materials
Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell...
NMPA(China) approves Tuoyi + chemotherapy to treat NSCLC without EGFR mutations or ALK fusions
The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab (Tuoyi) plus pemetrexed and platinum as a frontline treatment in patients with unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR mutations or ALK fusions
Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)
Increased activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway leads to numerous hallmarks of cancer and this pathway represents an attractive target for novel anticancer therapies. In NSCLC, the PI3K/Akt/mTOR pathway has been heavily implicated in both tumorigenesis and the progression of disease.
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes. The investigators...
Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to treatment with EGFR Tyrosine Kinase Inhibitors (TKI) in firs
To evaluate the disease control rate (CR, PR, SD) of oral vinorelbine as a single agent in patients with lung...
Oncologic Drugs Advisory Committee Meeting negative on poziotinib for the treatment of patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations
Spectrum Pharmaceuticals announced that the FDA's Oncologic Drugs Advisory Committee (“ODAC”) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations
An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced...